Markets:

Overview

News

Currencies

International

Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

4.400 +0.340 (+8.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Atai Beckley N.V - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Analyst Expectations For ATAI Life Sciences's Future ↗

October 22, 2025

Via Benzinga

Why Atai Life Sciences Stock Was So Lively This Week ↗

October 17, 2025

The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts.

Via The Motley Fool

Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides

October 14, 2025

As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This...

Via MarketMinute

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside ↗

October 13, 2025

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.

Via Benzinga

Alibaba, Lithium Americas And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews ↗

September 23, 2025

Via Benzinga

Why Atai Life Sciences Stock Crushed It on Tuesday ↗

September 23, 2025

Investors cheered good news from the lab delivered by the company.

Via The Motley Fool

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients ↗

September 23, 2025

Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026.

Via Benzinga

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% ↗

September 18, 2025

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

Via Benzinga

Topics Artificial Intelligence

Atai Life Sciences Revenue Jumps 163% ↗

August 14, 2025

Via The Motley Fool

Topics Intellectual Property

This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

July 30, 2025

Via Benzinga

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗

July 29, 2025

Via Benzinga

Why Is ATAI Life Sciences Stock Trading Lower On Monday? ↗

July 28, 2025

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.

Via Benzinga

What's going on in today's pre-market session ↗

July 28, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 28, 2025

Via Benzinga

US Stocks Likely To Open Higher As US-EU Ink Trade Deal: Tesla, Palantir, UnitedHealth In Focus ↗

July 28, 2025

U.S. stock futures rose on Monday after ending higher on Friday. Futures of major benchmark indices were higher.

Via Benzinga

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

July 28, 2025

Via Benzinga

Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday ↗

July 28, 2025

Via Benzinga

Top movers in Friday's after hours session ↗

July 25, 2025

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June ↗

July 01, 2025

Via Benzinga

Which stocks are experiencing notable movement on Tuesday? ↗

July 01, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday ↗

July 01, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 01, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data ↗

July 01, 2025

Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients.

Via Benzinga

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

July 01, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 04, 2025

Via Benzinga

Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip ↗

June 02, 2025

The merger focuses on creating a combined company focused on psychedelic mental health therapies.

Via Stocktwits

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer ↗

May 21, 2025

Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.